Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results

Joel E. Gallant, Ellen Koenig, Jaime Andrade-Villanueva, Ploenchan Chetchotisakd, Edwin Dejesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee, Andrew K. Cheng

Research output: Contribution to journal › Article › peer-review

99 Scopus citations

Fingerprint

Dive into the research topics of 'Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results'. Together they form a unique fingerprint.

Medicine & Life Sciences